



SAW CAS



isolated  
ring fu  
final  
query

chain nodes :

13 14 15

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 16 17 18 19 20 21

chain bonds :

5-13 6-9 13-14 14-15 15-17

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 16-17  
16-21 17-18 18-19 19-20 20-21

exact/norm bonds :

5-13 6-9 7-8 7-12 8-9 9-10 10-11 11-12 13-14 14-15 15-17

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom  
10:Atom 11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:Atom  
17:Atom 18:Atom 19:Atom 20:Atom 21:Atom

09/988966

=> s l1

SAMPLE SEARCH INITIATED 12:12:29 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 19 TO ITERATE

100.0% PROCESSED 19 ITERATIONS  
SEARCH TIME: 00.00.01

15 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 119 TO 641  
PROJECTED ANSWERS: 68 TO 532

L2 15 SEA SSS SAM L1

=> d l2 1-5

09/988966

L2 ANSWER 1 OF 15 REGISTRY COPYRIGHT 2003 ACS

RN 428816-11-9 REGISTRY

CN Pyrazine, 2-[2-[3-[(4-methyl-1-piperazinyl)methyl]phenoxy]ethoxy]-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)

OTHER NAMES:


CN 2-(1-Piperazinyl)-3-[2-[3-(4-methyl-1-piperazinylmethyl)phenoxy]ethoxy]pyrazine

FS 3D CONCORD

MF C22 H32 N6 O2

SR CA

LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

09/988966

L2 ANSWER 2 OF 15 REGISTRY COPYRIGHT 2003 ACS

RN 313658-97-8 REGISTRY

CN Pyrazine, 2-[2-(3-methoxyphenoxy)ethoxy]-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)

OTHER NAMES:


CN 2-(3-Methoxyphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether

FS 3D CONCORD

MF C17 H22 N4 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1962 TO DATE)

2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

09/988966

L2 ANSWER 3 OF 15 REGISTRY COPYRIGHT 2003 ACS

RN 313658-12-7 REGISTRY

CN Pyrazine, 2-[2-(2,5-dimethoxyphenoxy)ethoxy]-3-[(2R)-2-methyl-1-piperazinyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN (2R)-Methyl-1-[3-(2,5-dimethoxyphenoxyethoxy)-2-pyrazinyl]piperazine maleate

FS STEREOSEARCH

MF C19 H26 N4 O4 . C4 H4 O4

SR CA


LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 313658-11-6

CMF C19 H26 N4 O4

Absolute stereochemistry.




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



2 REFERENCES IN FILE CA (1962 TO DATE)

2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

09/988966

L2 ANSWER 4 OF 15 REGISTRY COPYRIGHT 2003 ACS

RN 313657-54-4 REGISTRY

CN Pyrazine, 2-[2-[(2,3-dihydro-7-benzofuranyl)oxy]ethoxy]-3-(1-piperazinyl)-  
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-(2,3-Dihydrobenzofuran-7-yloxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether


FS 3D CONCORD

MF C18 H22 N4 O3

CI COM

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1962 TO DATE)


2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

09/988966

L2 ANSWER 5 OF 15 REGISTRY COPYRIGHT 2003 ACS  
RN 313656-53-0 REGISTRY  
CN 1-Naphthalenamine, 6-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]-,  
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C20 H23 N5 O2 . C4 H4 O4  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1


CRN 313656-52-9  
CMF C20 H23 N5 O2



CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.



2 REFERENCES IN FILE CA (1962 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

09/988966

=> d 6-10



09/988966

L2 ANSWER 6 OF 15 REGISTRY COPYRIGHT 2003 ACS

RN 313656-52-9 REGISTRY


CN 1-Naphthalenamine, 6-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]- (9CI)  
(CA INDEX NAME)

FS 3D CONCORD

MF C20 H23 N5 O2

CI COM

SR CA



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

09/988966

L2 ANSWER 7 OF 15 REGISTRY COPYRIGHT 2003 ACS

RN 313655-90-2 REGISTRY

CN Pyrazine, 2-[2-(3-butoxyphenoxy)ethoxy]-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-[2-(3-Butoxyphenoxy)ethoxy]-3-(1-piperazinyl)pyrazine


FS 3D CONCORD

MF C20 H28 N4 O3

CI COM

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1962 TO DATE)

2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

09/988966

L2 ANSWER 8 OF 15 REGISTRY COPYRIGHT 2003 ACS

RN 313655-88-8 REGISTRY

CN Pyrazine, 2-[2-(1,3-benzodioxol-5-yloxy)ethoxy]-3-(1-piperazinyl)- (9CI)  
(CA INDEX NAME)

OTHER NAMES:


CN 2-[2-(1,3-Benzodioxol-5-yloxy)ethoxy]-3-(1-piperazinyl)pyrazine

FS 3D CONCORD

MF C17 H20 N4 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1962 TO DATE)

2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

09/988966

L2 ANSWER 9 OF 15 REGISTRY COPYRIGHT 2003 ACS

RN 313655-69-5 REGISTRY

CN Benzenemethanol, 3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]-,  
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN [3-[2-[[3-(1-Piperazinyl)-2-pyrazinyl]oxy]ethoxy]phenyl]methanol maleate

FS STEREOSEARCH

MF C17 H22 N4 O3 . x C4 H4 O4


SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 313655-68-4

CMF C17 H22 N4 O3




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




2 REFERENCES IN FILE CA (1962 TO DATE)

2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

09/988966

L2 ANSWER 10 OF 15 REGISTRY COPYRIGHT 2003 ACS  
RN 313655-32-2 REGISTRY  
CN Ethanone, 1-[7-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]-2-benzofuranyl]-  
, hydrochloride (9CI) (CA INDEX NAME)  
MF C20 H22 N4 O4 . x Cl H  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



● x HCl

2 REFERENCES IN FILE CA (1962 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

09/988966

=>

Uploading 09988966.str

L3           STRUCTURE UPLOADED

=> s 13

SAMPLE SEARCH INITIATED 12:14:25 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -       19 TO ITERATE

100.0% PROCESSED       19 ITERATIONS

9 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:   ONLINE   \*\*COMPLETE\*\*

BATCH   \*\*COMPLETE\*\*

PROJECTED ITERATIONS:       119 TO       641

PROJECTED ANSWERS:           9 TO       360

L4           9 SEA SSS SAM L3

=> s 13 sss full

FULL SEARCH INITIATED 12:14:38 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED -       297 TO ITERATE

100.0% PROCESSED       297 ITERATIONS

159 ANSWERS

SEARCH TIME: 00.00.01

L5           159 SEA SSS FUL L3

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.55

166.76

FILE 'CAPLUS' ENTERED AT 12:14:51 ON 02 JAN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 ~ 2 Jan 2003 VOL 138 ISS 1

FILE LAST UPDATED: 1 Jan 2003 (20030101/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use

09/988966

the CAS Roles thesaurus (/RL field) in this file.


=> s 15

L6            3 L5


=> d 16 1-3 bib abs hitstr

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS  
 AN 2002:790220 CAPLUS  
 DN 137:294982  
 TI Preparation of piperazinyldipyrzinyl aryloxyalkyl ethers as 5-HT<sub>2C</sub> receptor agonists  
 IN Nilsson, Bjorn; Tejbrant, Jan; Pelcman, Benjamin; Ringberg, Erik; Thor, Markus; Nilsson, Jonas; Jonsson, Mattias  
 PA Biovitrum AB, Swed.  
 SO U.S., 45 pp., Cont.-in-part of U.S. Ser. No. 573,348, abandoned.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6465467	B1	20021015	US 2000-589282	20000608
PRAI	SE 1999-1884	A	19990521		
	US 1999-137527P	P	19990603		
	US 2000-573348	B2	20000519		
OS	MARPAT 137:294982				
GI					



I




II

AB The title compds. (I) [wherein X and Y = independently O, S, or NR<sub>7</sub>; R and R<sub>1</sub> = independently H, alkyl, or halo; or C<sub>2</sub>RR<sub>1</sub> = optionally halo substituted benzene or thiophene; R<sub>2</sub> = H, OH, or alkyl; R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> = independently H or alkyl; R<sub>6</sub> = H or alkyl; or CYR<sub>6</sub>R<sub>8</sub> for a 5-6 membered heterocycle; R<sub>7</sub> = H or alkyl, preferably Me or Et; R<sub>8</sub> = (un)substituted (hetero)aryl; m and n = independently 1 or 2; or pharmaceutically acceptable salts, hydrates, geometric isomers, tautomers, optical isomers, N-oxides, and prodrugs thereof] were prepd. and tested as 5-HT<sub>2C</sub> receptor agonists. For instance, 2,3-dichloropyrazine and 2-phenoxyethanol were treated with t-BuONa in dioxane to give 2-chloro-3-(2-phenoxyethoxy)pyrazine (62%). The halopyrazine, piperazine, and K<sub>2</sub>CO<sub>3</sub> in MeCN were stirred and heated to afford the desired 2-(phenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether (II) in 65% yield, which was then converted to the maleate salt. In competition expts., I showed affinity for 5-HT<sub>2C</sub> receptor protein with K<sub>i</sub> values typically ranging from 1 nM to 1500 nM and specific values ranging from 5 nM to 377 nM for twelve compds. I exhibited agonist efficacy at the 5-HT<sub>2C</sub> receptor by mobilizing intracellular Ca in transfected HEK293 cells with max. responses in the range of 20-100% relative to the max. response of 5-HT (serotonin) at a concn. of 1 .mu.M. Acute toxicity studies in mice following oral




administration of I showed that mortality typically occurred at doses between 200 mg/kg to 450 mg/kg body wt. I are useful for the treatment of serotonin-related central nervous system disorders, such as eating disorders, memory disorders, schizophrenia, mood disorders, anxiety disorders, pain, sexual dysfunctions, and urinary disorders (no data).

IT **313653-94-0P**, 2-(Phenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether  
**313655-66-2P**, N-Phenyl-3-[2-[[3-(1-piperazinyl)-2-pyrazinyl]oxy]ethoxy]aniline **313655-69-5P**, [3-[2-[[3-(1-piperazinyl)-2-pyrazinyl]oxy]ethoxy]phenyl]methanol Maleate  
**313655-74-2P**, 2-[2-[3-(Methoxymethyl)phenoxy]ethoxy]-3-(1-piperazinyl)pyrazine **313655-77-5P**, 3-[2-[[3-(1-piperazinyl)-2-pyrazinyl]oxy]ethoxy]benzamide **313655-79-7P** **313655-82-2P**, 2-(1-piperazinyl)-3-[2-[3-(trifluoromethoxy)phenoxy]ethoxy]pyrazine  
**313655-90-2P**, 2-[2-(3-Butoxyphenoxy)ethoxy]-3-(1-piperazinyl)pyrazine **313655-93-5P**, 2-[2-(3-Trifluoromethylphenoxy)ethoxy]-3-(1-piperazinyl)pyrazine  
**313655-94-6P** **313655-99-1P**, 2-[4-[2-[[3-(1-piperazinyl)-2-pyrazinyl]oxy]ethoxy]phenoxy]ethanol **313656-01-8P**, 2-[3-(2-[[3-(1-piperazinyl)-2-pyrazinyl]oxy]ethoxy)phenoxy]ethanol  
**313657-07-7P**, 2-(2-Phenoxy)ethyl 3-(2-methyl-1-piperazinyl)-2-pyrazinyl ether **313658-60-5P**, 2-[2-[3-(2-Methoxyethoxy)phenoxy]ethoxy]-3-(1-piperazinyl)pyrazine  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (prepn. of heterocyclpyrazinyl aryloxyalkyl ether 5-HT<sub>2C</sub> receptor agonists from aryloxyalkanols, halopyrazines, and heterocycles)  
 RN 313653-94-0 CAPLUS  
 CN Pyrazine, 2-(2-phenoxyethoxy)-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 313655-66-2 CAPLUS  
 CN Benzenamine, N-phenyl-3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]- (9CI)  
 (CA INDEX NAME)




RN 313655-69-5 CAPLUS  
 CN Benzenemethanol, 3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

09/988966

CM 1

CRN 313655-68-4

CMF C17 H22 N4 O3




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 313655-74-2 CAPLUS


CN Pyrazine, 2-[2-[3-(methoxymethyl)phenoxy]ethoxy]-3-(1-piperazinyl)- (9CI)  
(CA INDEX NAME)



RN 313655-77-5 CAPLUS


CN Benzamide, 3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]- (9CI) (CA INDEX NAME)

09/988966




RN 313655-79-7 CAPLUS

CN Benzenamine, N-phenyl-4-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]- (9CI)  
(CA INDEX NAME)



RN 313655-82-2 CAPLUS


CN Pyrazine, 2-(1-piperazinyl)-3-[2-[3-(trifluoromethoxy)phenoxy]ethoxy]-  
(9CI) (CA INDEX NAME)



RN 313655-90-2 CAPLUS


CN Pyrazine, 2-[2-(3-butoxyphenoxy)ethoxy]-3-(1-piperazinyl)- (9CI) (CA  
INDEX NAME)

09/988966




RN 313655-93-5 CAPLUS

CN Pyrazine, 2-(1-piperazinyl)-3-[2-[3-(trifluoromethyl)phenoxy]ethoxy]-  
(9CI) (CA INDEX NAME)



RN 313655-94-6 CAPLUS


CN Pyrazine, 2-[2-([1,1'-biphenyl]-3-yloxy)ethoxy]-3-(1-piperazinyl)- (9CI)  
(CA INDEX NAME)



RN 313655-99-1 CAPLUS


CN Ethanol, 2-[4-[2-[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenoxy]- (9CI)  
(CA INDEX NAME)

09/988966




RN 313656-01-8 CAPLUS

CN Ethanol, 2-[3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenoxy]- (9CI)  
(CA INDEX NAME)




RN 313657-07-7 CAPLUS

CN Pyrazine, 2-(2-methyl-1-piperazinyl)-3-(2-phenoxyethoxy)- (9CI) (CA INDEX NAME)



RN 313658-60-5 CAPLUS

CN Pyrazine, 2-[2-[3-(2-methoxyethoxy)phenoxy]ethoxy]-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)



IT 313653-95-1P 313654-07-8P 313654-09-0P  
 313654-11-4P 313654-13-6P 313654-15-8P  
 313654-17-0P 313654-19-2P 313654-21-6P  
 313654-23-8P 313654-51-2P, 2-(Phenoxy)ethyl  
 3-(3-methyl-1-piperazinyl)-2-pyrazinyl ether 313654-52-3P,  
 2-(4-Chlorophenoxy)ethyl 3-(3-methyl-1-piperazinyl)-2-pyrazinyl ether  
 313654-53-4P, 2-(2-Methoxyphenoxy)-1-methylethyl  
 3-(3-methyl-1-piperazinyl)-2-pyrazinyl ether 313654-56-7P,  
 2-(Phenoxy)ethyl 3-(4-ethyl-1-piperazinyl)-2-pyrazinyl ether  
 313654-57-8P, 2-(2-Chlorophenoxy)ethyl 3-(4-ethyl-1-piperazinyl)-2-  
 pyrazinyl ether 313654-58-9P, 2-(4-Chlorophenoxy)ethyl  
 3-(4-ethyl-1-piperazinyl)-2-pyrazinyl ether 313654-60-3P,  
 2-(2-Methoxyphenoxy)-1-methylethyl 3-(4-ethyl-1-piperazinyl)-2-pyrazinyl  
 ether 313654-61-4P, 2-(3-Bromophenoxy)ethyl 3-(1-piperazinyl)-2-  
 pyrazinyl ether 313654-82-9P, 2-(2-Methoxyphenoxy)ethyl  
 3-(1-piperazinyl)-2-pyrazinyl ether 313654-86-3P,  
 2-(4-n-Butoxyphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether  
 Trifluoroacetate 313654-87-4P, 2-(2-Isopropoxyphenoxy)ethyl  
 3-(1-piperazinyl)-2-pyrazinyl ether 313654-89-6P,  
 2-(2,5-Difluorophenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether  
 313654-90-9P, 2-(2,5-Difluorophenoxy)ethyl 3-(1-piperazinyl)-2-  
 pyrazinyl ether Trifluoroacetate 313654-91-0P,  
 2-(3,5-Dimethoxyphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether  
 313654-92-1P, Pyrazine, 2-[2-(2-methoxy-5-nitrophenoxy)ethoxy]-3-  
 (1-piperazinyl)-, hydrochloride (2:1) 313654-94-3P,  
 2-(2,6-Dimethoxyphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether  
 Trifluoroacetate 313654-95-4P, 2-(2,3-Dimethoxyphenoxy)ethyl  
 3-(1-piperazinyl)-2-pyrazinyl ether 313654-97-6P,  
 2-(2-Acetylphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether  
 Trifluoroacetate 313654-99-8P, 2-(2-Acetyl-5-  
 methoxyphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether Trifluoroacetate  
 313655-01-5P, 2-(2-Acetyl-3,5-dimethoxyphenoxy)ethyl  
 3-(1-piperazinyl)-2-pyrazinyl ether Trifluoroacetate 313655-04-8P  
 , 2-(2-Fluoro-6-methoxyphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether  
 313655-05-9P, 2-(2-Methoxy-4-methylphenoxy)ethyl  
 3-(1-piperazinyl)-2-pyrazinyl ether 313655-08-2P,  
 2-(2-Chloro-4-methoxyphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether  
 313655-09-3P, 2-[2-[2-Fluoro-5-(trifluoromethyl)phenoxy]ethoxy]-3-  
 (1-piperazinyl)pyrazine 313655-12-8P, 2-[2-[3-  
 (Methylsulfonyl)phenoxy]ethoxy]-3-(1-piperazinyl)pyrazine  
 313655-14-0P, 2-(2,3,6-Trifluorophenoxy)ethyl 3-(1-piperazinyl)-2-  
 pyrazinyl ether 313655-15-1P, 2-(2,4,5-Trifluorophenoxy)ethyl  
 3-(1-piperazinyl)-2-pyrazinyl ether 313655-16-2P,  
 2-(2-Hydroxyphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether  
 313655-17-3P, 2-(3-Hydroxyphenoxy)ethyl 3-(1-piperazinyl)-2-  
 pyrazinyl ether 313655-18-4P, 2-[3-(4-Morpholinyl)phenoxy]ethyl  
 3-(1-piperazinyl)-2-pyrazinyl ether 313655-21-9P,  
 2-(2-Allylphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether  
 313655-22-0P, 2-(3-Aminophenoxy)ethyl 3-(1-piperazinyl)-2-  
 pyrazinyl ether 313655-24-2P, 2-(2,6-Difluorophenoxy)ethyl  
 3-(1-piperazinyl)-2-pyrazinyl ether 313655-33-3P,  
 3-(Phenoxy)propyl 3-(1-piperazinyl)-2-pyrazinyl ether Dihydrochloride  
 313655-34-4P, 2-(2-Trifluoromethylphenoxy)ethyl  
 3-(1-piperazinyl)-2-pyrazinyl ether 313655-37-7P,  
 2-(2-Methylthiophenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether Maleate  
 313655-39-9P, 2-(2-Methylphenoxy)ethyl 3-(1-piperazinyl)-2-  
 pyrazinyl ether Maleate 313655-40-2P, 2-(2,5-  
 Dimethylphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether

**313655-41-3P**, 2-(2-Fluorophenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether **313655-42-4P**, 2-(2-Fluorophenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether Maleate **313655-44-6P**, 2-(2-Cyanophenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether Maleate **313655-46-8P 313655-47-9P**, 4-(Phenoxy)butyl 3-(1-piperazinyl)-2-pyrazinyl ether Dihydrochloride **313655-49-1P**, 2-[2-(2-Fluoro-5-methylphenoxy)ethoxy]-3-(1-piperazinyl)pyrazine Fumarate **313655-52-6P**, 2-[2-(5-Fluoro-2-methoxyphenoxy)ethoxy]-3-(1-piperazinyl)pyrazine Fumarate **313655-54-8P**, 2-[2-(3-Fluorophenoxy)ethoxy]-3-(1-piperazinyl)pyrazine Maleate **313655-57-1P**, 2-[2-(3-Acetylphenoxy)ethoxy]-3-(1-piperazinyl)pyrazine **313655-58-2P**, 2-[2-(3-Acetylphenoxy)ethoxy]-3-(1-piperazinyl)pyrazine Maleate **313655-59-3P**, 2-[2-(3-Cyanophenoxy)ethoxy]-3-(1-piperazinyl)pyrazine **313655-61-7P**, 2-[2-(2,3-Difluorophenoxy)ethoxy]-3-(1-piperazinyl)pyrazine Fumarate **313655-64-0P**, 2-[2-(2,3,5-Trifluorophenoxy)ethoxy]-3-(1-piperazinyl)pyrazine Fumarate **313655-67-3P**, N-Phenyl-3-[2-[[3-(1-piperazinyl)-2-pyrazinyl]oxy]ethoxy]aniline Fumarate **313655-75-3P**, 2-[2-[3-(Methoxymethyl)phenoxy]ethoxy]-3-(1-piperazinyl)pyrazine Maleate **313655-78-6P**, 3-[2-[[3-(1-Piperazinyl)-2-pyrazinyl]oxy]ethoxy]benzamide Maleate **313655-80-0P**, N-Phenyl-4-[2-[[3-(1-piperazinyl)-2-pyrazinyl]oxy]ethoxy]aniline Maleate **313655-81-1P**, N-[4-[2-[[3-(1-Piperazinyl)-2-pyrazinyl]oxy]ethoxy]phenyl]acetamide **313655-83-3P**, 2-(1-Piperazinyl)-3-[2-[3-(trifluoromethoxy)phenoxy]ethoxy]pyrazine Maleate **313655-91-3P**, 2-[2-(3-Butoxyphenoxy)ethoxy]-3-(1-piperazinyl)pyrazine Maleate **313655-95-7P**, 2-[2-[(1,1'-Biphenyl)-3-yloxy]ethoxy]-3-(1-piperazinyl)pyrazine Maleate **313655-97-9P**, 2-[2-(3-Acetamidophenoxy)ethoxy]-3-(1-piperazinyl)pyrazine Maleate **313656-00-7P**, 2-[4-[2-[[3-(1-Piperazinyl)-2-pyrazinyl]oxy]ethoxy]phenoxy]ethanol Maleate **313656-02-9P**, 2-[3-(2-[[3-(1-Piperazinyl)-2-pyrazinyl]oxy]ethoxy)phenoxy]ethanol Maleate **313656-50-7P**, 2-[2-(2-Methoxy-5-methylphenoxy)ethoxy]-3-(1-piperazinyl)pyrazine Maleate **313657-06-6P**, Pyrazine, 2-(4-methyl-1-piperazinyl)-3-(2-phenoxyethoxy)-, monohydrochloride **313657-08-8P**, 2-(2-Phenoxy)ethyl 3-(2-methyl-1-piperazinyl)-2-pyrazinyl ether Maleate **313657-11-3P**, (2R)-Methyl-1-[3-(2-phenoxyethoxy)-2-pyrazinyl]piperazine Hydrochloride **313657-17-9P**, (2S)-Methyl-1-[3-(2-phenoxyethoxy)-2-pyrazinyl]piperazine Hydrochloride **313657-46-4P**, 5,6-Dimethyl-2-(2-phenoxyethoxy)-3-(1-piperazinyl)pyrazine Dihydrochloride **313658-09-2P**, 4-Methoxy-N,N-dimethyl-3-[2-[[3-(2R)-2-methylpiperazinyl]-2-pyrazinyl]oxy]ethoxy]aniline Fumarate **313658-12-7P**, (2R)-Methyl-1-[3-(2,5-dimethoxyphenoxyethoxy)-2-pyrazinyl]piperazine Maleate **313658-45-6P**, 2-[2-[3-(2-Fluoroethoxy)phenoxy]ethoxy]-3-(1-piperazinyl)pyrazine Trifluoroacetate **313658-47-8P**, 2-[2-[3-[2-(4-Methyl-1,3-thiazol-5-yl)ethoxy]phenoxy]ethoxy]-3-(1-piperazinyl)pyrazine **313658-48-9P**, Pyrazine, 2-[2-[3-[2-(4-methyl-5-thiazolyl)ethoxy]phenoxy]ethoxy]-3-(1-piperazinyl)-, trifluoroacetate **313658-50-3P**, 2-[2-[3-(Cyclopropylmethoxy)phenoxy]ethoxy]-3-(1-piperazinyl)pyrazine Trifluoroacetate **313658-52-5P**, 2-[2-[3-(3-Butenyloxy)phenoxy]ethoxy]-3-(1-piperazinyl)pyrazine Trifluoroacetate **313658-54-7P**, N,N-Dimethyl-N-[2-[3-[2-[[3-(1-piperazinyl)-2-pyrazinyl]oxy]ethoxy]phenoxy]ethyl]amine **313658-55-8P**, N,N-Dimethyl-N-[2-[3-(2-[[3-(1-piperazinyl)-2-pyrazinyl]oxy]ethoxy)phenoxy]ethyl]amine Trifluoroacetate

**313658-57-0P**, 2-(1-Piperazinyl)-3-[2-[3-(tetrahydro-2H-pyran-4-yloxy)phenoxy]ethoxy]pyrazine **313658-58-1P**, 2-(1-Piperazinyl)-3-[2-[3-(tetrahydro-2H-pyran-4-yloxy)phenoxy]ethoxy]pyrazine Trifluoroacetate **313658-63-8P**, 1-[2-[3-[2-[[3-(1-Piperazinyl)-2-pyrazinyl]oxy]ethoxy]phenoxy]ethyl]-2-pyrrolidinone **313658-65-0P**, 2-(1-Piperazinyl)-3-[2-[3-(tetrahydro-3-furanyloxy)phenoxy]ethoxy]pyrazine **313658-67-2P**, 2-(1-Piperazinyl)-3-[2-[3-(tetrahydro-3-furanylmethoxy)phenoxy]ethoxy]pyrazine **313658-70-7P**, 2-[[3-[2-[[3-(1-Piperazinyl)-2-pyrazinyl]oxy]ethoxy]phenoxy]methyl]benzonitrile **313658-71-8P**, 2-[[3-[2-[[3-(1-Piperazinyl)-2-pyrazinyl]oxy]ethoxy]phenoxy]methyl]benzonitrile Trifluoroacetate **313658-75-2P**, 2-[2-[3-(Benzyloxy)phenoxy]ethoxy]-3-(1-piperazinyl)pyrazine Trifluoroacetate **313658-78-5P**, 2-(1-Piperazinyl)-3-[2-[3-[2-(2-pyridinyl)ethoxy]phenoxy]ethoxy]pyrazine **313658-79-6P 313658-97-8P 313659-07-3P**, (R)-2-Methyl-1-[3-(2-phenoxyethoxy)-2-pyrazinyl]piperazine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heterocyclpyrazinyl aryloxyalkyl ether 5-HT<sub>2C</sub> receptor agonists from aryloxyalkanols, halopyrazines, and heterocycles)


RN 313653-95-1 CAPLUS

CN Pyrazine, 2-(2-phenoxyethoxy)-3-(1-piperazinyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313653-94-0

CMF C16 H20 N4 O2




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 313654-07-8 CAPLUS


CN Pyrazine, 2-[2-(2-bromophenoxy)ethoxy]-3-(1-piperazinyl)-, ethanedioate (9CI) (CA INDEX NAME)

CM 1




09/988966

CRN 313654-06-7  
CMF C16 H19 Br N4 O2



CM 2


CRN 144-62-7  
CMF C2 H2 O4



RN 313654-09-0 CAPLUS  
CN Pyrazine, 2-[2-(2-chlorophenoxy)ethoxy]-3-(1-piperazinyl)-, ethanedioate  
(9CI) (CA INDEX NAME)

CM 1


CRN 313654-08-9  
CMF C16 H19 Cl N4 O2



CM 2

CRN 144-62-7  
CMF C2 H2 O4


09/988966



RN 313654-11-4 CAPLUS  
CN Pyrazine, 2-[2-(4-chlorophenoxy)ethoxy]-3-(1-piperazinyl)-, ethanedioate  
(9CI) (CA INDEX NAME)


CM 1

CRN 313654-10-3  
CMF C16 H19 Cl N4 O2



CM 2


CRN 144-62-7  
CMF C2 H2 O4



RN 313654-13-6 CAPLUS  
CN Pyrazine, 2-(2-phenoxypropoxy)-3-(1-piperazinyl)-, ethanedioate (9CI) (CA  
INDEX NAME)

CM 1

CRN 313654-12-5  
CMF C17 H22 N4 O2




09/988966

CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 313654-15-8 CAPLUS

CN Pyrazine, 2-(1-methyl-2-phenoxyethoxy)-3-(1-piperazinyl)-, ethanedioate  
(9CI) (CA INDEX NAME)

CM 1

CRN 313654-14-7


CMF C17 H22 N4 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 313654-17-0 CAPLUS


CN Pyrazine, 2-[2-(2-methoxyphenoxy)-1-methylethoxy]-3-(1-piperazinyl)-, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 313654-16-9

CMF C18 H24 N4 O3


09/988966



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 313654-19-2 CAPLUS

CN Pyrazine, 2-[2-(3-methoxyphenoxy)-1-methylethoxy]-3-(1-piperazinyl)-, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 313654-18-1


CMF C18 H24 N4 O3



CM 2

CRN 144-62-7

CMF C2 H2 O4



09/988966


RN 313654-21-6 CAPLUS

CN Pyrazine, 2-[1-methyl-2-(2-methylphenoxy)ethoxy]-3-(1-piperazinyl)-, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 313654-20-5


CMF C18 H24 N4 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 313654-23-8 CAPLUS

CN Pyrazine, 2-[1-methyl-2-(4-methylphenoxy)ethoxy]-3-(1-piperazinyl)-, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 313654-22-7


CMF C18 H24 N4 O2




CM 2

09/988966


CRN 144-62-7  
CMF C2 H2 O4




RN 313654-51-2 CAPLUS  
CN Pyrazine, 2-(3-methyl-1-piperazinyl)-3-(2-phenoxyethoxy)- (9CI) (CA INDEX NAME)



RN 313654-52-3 CAPLUS  
CN Pyrazine, 2-[2-(4-chlorophenoxy)ethoxy]-3-(3-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 313654-53-4 CAPLUS  
CN Pyrazine, 2-[2-(2-methoxyphenoxy)-1-methylethoxy]-3-(3-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 313654-56-7 CAPLUS


09/988966

CN    Pyrazine, 2-(4-ethyl-1-piperazinyl)-3-(2-phenoxyethoxy)- (9CI)    (CA INDEX NAME)




RN    313654-57-8    CAPLUS

CN    Pyrazine, 2-[2-(2-chlorophenoxy)ethoxy]-3-(4-ethyl-1-piperazinyl)- (9CI)  
      (CA INDEX NAME)



RN    313654-58-9    CAPLUS


CN    Pyrazine, 2-[2-(4-chlorophenoxy)ethoxy]-3-(4-ethyl-1-piperazinyl)- (9CI)  
      (CA INDEX NAME)



RN    313654-60-3    CAPLUS


CN    Pyrazine, 2-(4-ethyl-1-piperazinyl)-3-[2-(2-methoxyphenoxy)-1-methylethoxy]- (9CI)    (CA INDEX NAME)

09/988966




RN 313654-61-4 CAPLUS

CN Pyrazine, 2-[2-(3-bromophenoxy)ethoxy]-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 313654-82-9 CAPLUS

CN Pyrazine, 2-[2-(2-methoxyphenoxy)ethoxy]-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 313654-86-3 CAPLUS

CN Pyrazine, 2-[2-(4-butoxyphenoxy)ethoxy]-3-(1-piperazinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 313654-85-2

CMF C20 H28 N4 O3




09/988966



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 313654-87-4 CAPLUS


CN Pyrazine, 2-[2-[2-(1-methylethoxy)phenoxy]ethoxy]-3-(1-piperazinyl)- (9CI)  
(CA INDEX NAME)



RN 313654-89-6 CAPLUS

CN Pyrazine, 2-[2-(2,5-difluorophenoxy)ethoxy]-3-(1-piperazinyl)- (9CI) (CA  
INDEX NAME)


09/988966



RN 313654-90-9 CAPLUS  
CN Pyrazine, 2-[2-(2,5-difluorophenoxy)ethoxy]-3-(1-piperazinyl)-,  
trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 313654-89-6  
CMF C16 H18 F2 N4 O2




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 313654-91-0 CAPLUS  
CN Pyrazine, 2-[2-(3,5-dimethoxyphenoxy)ethoxy]-3-(1-piperazinyl)- (9CI) (CA  
INDEX NAME)

09/988966



RN 313654-92-1 CAPLUS

CN Pyrazine, 2-[2-(2-methoxy-5-nitrophenoxy)ethoxy]-3-(1-piperazinyl)-,  
hydrochloride (2:1) (9CI) (CA INDEX NAME)



● 1/2 HCl


RN 313654-94-3 CAPLUS

CN Pyrazine, 2-[2-(2,6-dimethoxyphenoxy)ethoxy]-3-(1-piperazinyl)-,  
trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 313654-93-2

CMF C18 H24 N4 O4




09/988966

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 313654-95-4 CAPLUS

CN Pyrazine, 2-[2-(2,3-dimethoxyphenoxy)ethoxy]-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 313654-97-6 CAPLUS

CN Ethanone, 1-[2-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 313654-96-5

CMF C18 H22 N4 O3




CM 2

CRN 76-05-1

CMF C2 H F3 O2


09/988966



RN 313654-99-8 CAPLUS  
CN Ethanone, 1-[4-methoxy-2-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 313654-98-7  
CMF C19 H24 N4 O4



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 313655-01-5 CAPLUS  
CN Ethanone, 1-[2,4-dimethoxy-6-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 313655-00-4  
CMF C20 H26 N4 O5


09/988966



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 313655-04-8 CAPLUS


CN Pyrazine, 2-[2-(2-fluoro-6-methoxyphenoxy)ethoxy]-3-(1-piperazinyl)- (9CI)  
(CA INDEX NAME)



RN 313655-05-9 CAPLUS


CN Pyrazine, 2-[2-(2-methoxy-4-methylphenoxy)ethoxy]-3-(1-piperazinyl)- (9CI)  
(CA INDEX NAME)

09/988966




RN 313655-08-2 CAPLUS

CN Pyrazine, 2-[2-(2-chloro-4-methoxyphenoxy)ethoxy]-3-(1-piperazinyl)- (9CI)  
(CA INDEX NAME)



RN 313655-09-3 CAPLUS


CN Pyrazine, 2-[2-[2-fluoro-4-(trifluoromethyl)phenoxy]ethoxy]-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 313655-12-8 CAPLUS


CN Pyrazine, 2-[2-[3-(methylsulfonyl)phenoxy]ethoxy]-3-(1-piperazinyl)- (9CI)  
(CA INDEX NAME)

09/988966




RN 313655-14-0 CAPLUS

CN Pyrazine, 2-(1-piperazinyl)-3-[2-(2,3,6-trifluorophenoxy)ethoxy]- (9CI)  
(CA INDEX NAME)



RN 313655-15-1 CAPLUS

CN Pyrazine, 2-(1-piperazinyl)-3-[2-(2,4,5-trifluorophenoxy)ethoxy]- (9CI)  
(CA INDEX NAME)




RN 313655-16-2 CAPLUS

CN Phenol, 2-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]- (9CI) (CA INDEX  
NAME)




09/988966




RN 313655-17-3 CAPLUS

CN Phenol, 3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]- (9CI) (CA INDEX NAME)



RN 313655-18-4 CAPLUS


CN Morpholine, 4-[3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 313655-21-9 CAPLUS


CN Pyrazine, 2-(1-piperazinyl)-3-[2-[2-(2-propenyl)phenoxy]ethoxy]- (9CI) (CA INDEX NAME)

09/988966




RN 313655-22-0 CAPLUS

CN Benzenamine, 3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]- (9CI) (CA INDEX NAME)



RN 313655-24-2 CAPLUS


CN Pyrazine, 2-[2-(2,6-difluorophenoxy)ethoxy]-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 313655-33-3 CAPLUS

CN Pyrazine, 2-(3-phenoxypropoxy)-3-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)


09/988966



● 2 HCl

RN 313655-34-4 CAPLUS

CN Pyrazine, 2-(1-piperazinyl)-3-[2-[2-(trifluoromethyl)phenoxy]ethoxy]-  
(9CI) (CA INDEX NAME)




RN 313655-37-7 CAPLUS

CN Pyrazine, 2-[2-[2-(methylthio)phenoxy]ethoxy]-3-(1-piperazinyl)-,  
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-36-6

CMF C17 H22 N4 O2 S




CM 2

CRN 110-16-7

CMF C4 H4 O4

09/988966

Double bond geometry as shown.




RN 313655-39-9 CAPLUS

CN Pyrazine, 2-[2-(2-methylphenoxy)ethoxy]-3-(1-piperazinyl)-,  
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-38-8

CMF C17 H22 N4 O2




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 313655-40-2 CAPLUS


CN Pyrazine, 2-[2-(2,5-dimethylphenoxy)ethoxy]-3-(1-piperazinyl)- (9CI) (CA  
INDEX NAME)

09/988966



RN 313655-41-3 CAPLUS

CN Pyrazine, 2-[2-(2-fluorophenoxy)ethoxy]-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 313655-42-4 CAPLUS

CN Pyrazine, 2-[2-(2-fluorophenoxy)ethoxy]-3-(1-piperazinyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-41-3

CMF C16 H19 F N4 O2




CM 2

CRN 110-16-7

CMF C4 H4 O4

09/988966


Double bond geometry as shown.



RN 313655-44-6 CAPLUS  
CN Benzonitrile, 2-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]-,  
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 313655-43-5  
CMF C17 H19 N5 O2



CM 2


CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.




RN 313655-46-8 CAPLUS  
CN Pyrazine, 2-[2-([1,1'-biphenyl]-2-yloxy)ethoxy]-3-(1-piperazinyl)- (9CI)  
(CA INDEX NAME)

09/988966



RN 313655-47-9 CAPLUS  
CN Pyrazine, 2-(4-phenoxybutoxy)-3-(1-piperazinyl)-, dihydrochloride (9CI)  
(CA INDEX NAME)




● 2 HCl

RN 313655-49-1 CAPLUS  
CN Pyrazine, 2-[2-(2-fluoro-5-methylphenoxy)ethoxy]-3-(1-piperazinyl)-,  
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-48-0  
CMF C17 H21 F N4 O2




CM 2

CRN 110-17-8  
CMF C4 H4 O4

09/988966


Double bond geometry as shown.



RN 313655-52-6 CAPLUS  
CN Pyrazine, 2-[2-(5-fluoro-2-methoxyphenoxy)ethoxy]-3-(1-piperazinyl)-,  
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 313655-51-5  
CMF C17 H21 F N4 O3



CM 2

CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.




RN 313655-54-8 CAPLUS  
CN Pyrazine, 2-[2-(3-fluorophenoxy)ethoxy]-3-(1-piperazinyl)-,  
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-53-7  
CMF C16 H19 F N4 O2



09/988966




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 313655-57-1 CAPLUS

CN Ethanone, 1-[3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenyl]- (9CI)  
(CA INDEX NAME)



RN 313655-58-2 CAPLUS


CN Ethanone, 1-[3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenyl]-, (Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-57-1

CMF C18 H22 N4 O3

09/988966




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 313655-59-3 CAPLUS

CN Benzonitrile, 3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]- (9CI) (CA INDEX NAME)



RN 313655-61-7 CAPLUS


CN Pyrazine, 2-[2-(2,3-difluorophenoxy)ethoxy]-3-(1-piperazinyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-60-6

CMF C16 H18 F2 N4 O2

09/988966




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 313655-64-0 CAPLUS

CN Pyrazine, 2-(1-piperazinyl)-3-[2-(2,3,5-trifluorophenoxy)ethoxy]-,  
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-63-9

CMF C16 H17 F3 N4 O2




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




09/988966

RN 313655-67-3 CAPLUS  
CN Benzenamine, N-phenyl-3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]-,  
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 313655-66-2  
CMF C22 H25 N5 O2



CM 2

CRN 110-17-8  
CMF C4 H4 O4


Double bond geometry as shown.



RN 313655-75-3 CAPLUS  
CN Pyrazine, 2-[2-[3-(methoxymethyl)phenoxy]ethoxy]-3-(1-piperazinyl)-,  
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-74-2  
CMF C18 H24 N4 O3




CM 2

09/988966

CRN 110-16-7  
CMF C4 H4 O4


Double bond geometry as shown.



RN 313655-78-6 CAPLUS  
CN Benzanide, 3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]-,  
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 313655-77-5  
CMF C17 H21 N5 O3



CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.




RN 313655-80-0 CAPLUS  
CN Benzenamine, N-phenyl-4-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]-,  
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-79-7  
CMF C22 H25 N5 O2

09/988966




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 313655-81-1 CAPLUS

CN Acetamide, N-[4-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenyl]- (9CI)  
(CA INDEX NAME)



RN 313655-83-3 CAPLUS


CN Pyrazine, 2-(1-piperazinyl)-3-[2-[3-(trifluoromethoxy)phenoxy]ethoxy]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-82-2

CMF C17 H19 F3 N4 O3

09/988966




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 313655-91-3 CAPLUS

CN Pyrazine, 2-[2-(3-butoxyphenoxy)ethoxy]-3-(1-piperazinyl)-,  
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-90-2

CMF C20 H28 N4 O3




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.


09/988966



RN 313655-95-7 CAPLUS  
CN Pyrazine, 2-[2-([1,1'-biphenyl]-3-yloxy)ethoxy]-3-(1-piperazinyl)-,  
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 313655-94-6  
CMF C22 H24 N4 O2



CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.




RN 313655-97-9 CAPLUS  
CN Acetamide, N-[3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenyl]-,  
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-96-8  
CMF C18 H23 N5 O3



09/988966




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 313656-00-7 CAPLUS

CN Ethanol, 2-[4-[2-[[3-(1-piperazinyl)pyrazinyl]ethoxy]ethoxy]phenoxy]-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-99-1

CMF C18 H24 N4 O4




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.

09/988966




RN 313656-02-9 CAPLUS

CN Ethanol, 2-[3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenoxy]-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 313656-01-8

CMF C18 H24 N4 O4




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 313656-50-7 CAPLUS


CN Pyrazine, 2-[2-(2-methoxy-5-methylphenoxy)ethoxy]-3-(1-piperazinyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313656-49-4

CMF C18 H24 N4 O3

09/988966




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 313657-06-6 CAPLUS

CN Pyrazine, 2-(4-methyl-1-piperazinyl)-3-(2-phenoxyethoxy)-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 313657-08-8 CAPLUS


CN Pyrazine, 2-(2-methyl-1-piperazinyl)-3-(2-phenoxyethoxy)-,  
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313657-07-7

CMF C17 H22 N4 O2

09/988966




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 313657-11-3 CAPLUS

CN Pyrazine, 2-[(2R)-2-methyl-1-piperazinyl]-3-(2-phenoxyethoxy)-,  
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 313657-17-9 CAPLUS

CN Pyrazine, 2-[(2S)-2-methyl-1-piperazinyl]-3-(2-phenoxyethoxy)-,  
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/988966



● HCl

RN 313657-46-4 CAPLUS

CN Pyrazine, 2,3-dimethyl-5-(2-phenoxyethoxy)-6-(1-piperazinyl)-,  
dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 313658-09-2 CAPLUS


CN Benzenamine, 4-methoxy-N,N-dimethyl-3-[2-[[3-[(2R)-2-methyl-1-piperazinyl]pyrazinyl]oxy]ethoxy]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313658-08-1

CMF C20 H29 N5 O3

Absolute stereochemistry.




09/988966

CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 313658-12-7 CAPLUS


CN Pyrazine, 2-[2-(2,5-dimethoxyphenoxy)ethoxy]-3-[(2R)-2-methyl-1-piperazinyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313658-11-6

CMF C19 H26 N4 O4

Absolute stereochemistry.




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 313658-45-6 CAPLUS


CN Pyrazine, 2-[2-[3-(2-fluoroethoxy)phenoxy]ethoxy]-3-(1-piperazinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 313658-44-5

09/988966


CMF C18 H23 F N4 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 313658-47-8 CAPLUS

CN Pyrazine, 2-[2-[3-[2-(4-methyl-5-thiazolyl)ethoxy]phenoxy]ethoxy]-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 313658-48-9 CAPLUS


CN Pyrazine, 2-[2-[3-[2-(4-methyl-5-thiazolyl)ethoxy]phenoxy]ethoxy]-3-(1-piperazinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 313658-47-8

CMF C22 H27 N5 O3 S


09/988966



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313658-50-3 CAPLUS

CN Pyrazine, 2-[2-[3-(cyclopropylmethoxy)phenoxy]ethoxy]-3-(1-piperazinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 313658-49-0

CMF C20 H26 N4 O3




CM 2

CRN 76-05-1

CMF C2 H F3 O2



09/988966




RN 313658-52-5 CAPLUS

CN Pyrazine, 2-[2-[3-(3-butenyloxy)phenoxy]ethoxy]-3-(1-piperazinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 313658-51-4


CMF C20 H26 N4 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 313658-54-7 CAPLUS

CN Ethanamine, N,N-dimethyl-2-[3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)




09/988966

RN 313658-55-8 CAPLUS  
CN Ethanamine, N,N-dimethyl-2-[3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenoxy]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 313658-54-7  
CMF C20 H29 N5 O3




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 313658-57-0 CAPLUS  
CN Pyrazine, 2-(1-piperazinyl)-3-[2-[3-[(tetrahydro-2H-pyran-4-yl)oxy]phenoxy]ethoxy]- (9CI) (CA INDEX NAME)




RN 313658-58-1 CAPLUS  
CN Pyrazine, 2-(1-piperazinyl)-3-[2-[3-[(tetrahydro-2H-pyran-4-yl)oxy]phenoxy]ethoxy]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


09/988966

CRN 313658-57-0  
CMF C21 H28 N4 O4




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 313658-63-8 CAPLUS  
CN 2-Pyrrolidinone, 1-[2-[3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 313658-65-0 CAPLUS  
CN Pyrazine, 2-(1-piperazinyl)-3-[2-[3-[(tetrahydro-2-furanyl)oxy]phenoxy]ethoxy]- (9CI) (CA INDEX NAME)

09/988966




RN 313658-67-2 CAPLUS

CN Pyrazine, 2-(1-piperazinyl)-3-[2-[3-[(tetrahydro-2-furanyl)methoxy]phenoxy]ethoxy]- (9CI) (CA INDEX NAME)



RN 313658-70-7 CAPLUS

CN Benzonitrile, 2-[[[3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 313658-71-8 CAPLUS

CN Benzonitrile, 2-[[[3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenoxy]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 313658-70-7

CMF C24 H25 N5 O3


C1CCN(CC1)c2ncnc2OCCOC3=CC=CC=C3OCC4=CC=CC=C4C#N

CRN 76-05-1  
CMF C2 H F3 O2




CM 1

CRN 313658-74-1  
CMF C23 H26 N4 O3




CRN 76-05-1  
CMF C2 H F3 O2

09/988966



RN 313658-78-5 CAPLUS

CN Pyrazine, 2-(1-piperazinyl)-3-[2-[3-[2-(2-pyridinyl)ethoxy]phenoxy]ethoxy]-  
(9CI) (CA INDEX NAME)




RN 313658-79-6 CAPLUS

CN Pyrazine, 2-(1-piperazinyl)-3-[2-[3-[2-(2-pyridinyl)ethoxy]phenoxy]ethoxy]-  
, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 313658-78-5


CMF C23 H27 N5 O3



CM 2

CRN 76-05-1


CMF C2 H F3 O2



09/988966


RN 313658-97-8 CAPLUS

CN Pyrazine, 2-[2-(3-methoxyphenoxy)ethoxy]-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 313659-07-3 CAPLUS

CN Pyrazine, 2-[(2R)-2-methyl-1-piperazinyl]-3-(2-phenoxyethoxy)- (9CI) (CA INDEX NAME)




Absolute stereochemistry.

IT **313655-71-9P**, 2-[2-[3-(Dimethoxymethyl)phenoxy]ethoxy]-3-(1-piperazinyl)pyrazine **313655-73-1P**, Benzaldehyde, 3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]-, acetate (10:17) **313657-10-2P**, 2-(2-Phenoxy)ethyl 3-(4-benzyl-2-methyl-1-piperazinyl)-2-pyrazinyl ether **313658-46-7P**, tert-Butyl 4-[3-[2-(3-hydroxyphenoxy)ethoxy]-2-pyrazinyl]-1-piperazinecarboxylate **313658-62-7P**, tert-Butyl 4-[3-[2-[3-(2-methoxyethoxy)phenoxy]ethoxy]-2-pyrazinyl]-1-piperazinecarboxylate  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of heterocyclpyrazinyl aryloxyalkyl ether 5-HT<sub>2C</sub> receptor agonists from aryloxyalkanols, halopyrazines, and heterocycles)

RN 313655-71-9 CAPLUS

CN Pyrazine, 2-[2-[3-(dimethoxymethyl)phenoxy]ethoxy]-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)

09/988966




RN 313655-73-1 CAPLUS

CN Benzaldehyde, 3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]-, acetate  
(10:17) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-72-0


CMF C17 H20 N4 O3



CM 2


CRN 64-19-7

CMF C2 H4 O2



RN 313657-10-2 CAPLUS

CN Pyrazine, 2-[2-methyl-4-(phenylmethyl)-1-piperazinyl]-3-(2-phenoxyethoxy)-  
(9CI) (CA INDEX NAME)






09/988966


RN 313658-46-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-[2-(3-hydroxyphenoxy)ethoxy]pyrazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 313658-62-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-[2-[3-(2-methoxyethoxy)phenoxy]ethoxy]pyrazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/988966


L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS  
AN 2002:391692 CAPLUS  
DN 136:401780  
TI Preparation of piperazinyipyrazines as antagonists of serotonin 5-HT2  
receptor  
IN Nilsson, Bjoern; Scobie, Martin  
PA Biovitrum AB, Swed.  
SO PCT Int. Appl., 32 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

APPS

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002040457	A1	20020523	WO 2001-SE2570	20011120
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2002103204	A1	20020801	US 2001-988966	20011119
	AU 2002015294	A5	20020527	AU 2002-15294	20011120
PRAI	SE 2000-4244	A	20001120		
	US 2000-253702P	P	20001128		
	WO 2001-SE2570	W	20011120		
OS	MARPAT 136:401780				
GI					



I



II

AB The title compds. [I; R1 = H, alkyl, alkenyl, etc.; R2 = H, alkyl, CH2OH, etc.; R3, R4 = H, alkyl, aryl, etc.; or R3 and R4 together with the carbon atoms to which they are bound form (un)substituted 5-6 membered (hetero)arom. ring; R5, R6 = H, alkoxyalkyl, hydroxyalkyl, etc.; or NR5R6 = (un)substituted satd. 4-7 membered heterocyclic ring which may contain an addnl. heteroatom; R7 = H, halo, Me, OMe, OEt; n = 1-3] which are ligands to the serotonin 5-HT2c receptor, were prepd. and formulated. E.g., a 5-step synthesis of II which showed Ki of 18 nM against 5-HT2C receptor binding, was given.

IT **428816-09-5P**, 2-(1-Piperazinyl)-3-[2-[3-(4-morpholinylmethyl)phenoxy]ethoxy]pyrazine **428816-10-8P**, 2-(1-Piperazinyl)-3-[2-[3-(1-pyrrolidinylmethyl)phenoxy]ethoxy]pyrazine **428816-11-9P**, 2-(1-Piperazinyl)-3-[2-[3-(4-methyl-1-piperazinylmethyl)phenoxy]ethoxy]pyrazine **428816-12-0P**, 2-(1-Piperazinyl)-3-[2-[3-[(2-methoxyethyl)amino]methyl]phenoxy]ethoxy]pyrazine **428816-13-1P**, 2-(1-Piperazinyl)-3-[2-[3-[(isopropylamino)methyl]phenoxy]ethoxy]pyrazine **428816-14-2P**, 2-(1-Piperazinyl)-3-[2-[3-[(3-methoxyphenylamino)methyl]phenoxy]ethoxy]pyrazine **428816-15-3P**, 2-(1-Piperazinyl)-3-[2-[3-[(2-hydroxyethylamino)methyl]phenoxy]ethoxy]pyrazine


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of piperazinylpyrazines as antagonists of serotonin 5-HT2 receptor)

RN 428816-09-5 CAPLUS


CN Morpholine, 4-[[[3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

09/988966




RN 428816-10-8 CAPLUS

CN Pyrazine, 2-(1-piperazinyl)-3-[2-[3-(1-pyrrolidinylmethyl)phenoxy]ethoxy]-  
(9CI) (CA INDEX NAME)



RN 428816-11-9 CAPLUS


CN Pyrazine, 2-[2-[3-[(4-methyl-1-piperazinyl)methyl]phenoxy]ethoxy]-3-(1-  
piperazinyl)- (9CI) (CA INDEX NAME)



RN 428816-12-0 CAPLUS


CN Benzenemethanamine, N-(2-methoxyethyl)-3-[2-[[3-(1-  
piperazinyl)pyrazinyl]oxy]ethoxy]- (9CI) (CA INDEX NAME)

09/988966




RN 428816-13-1 CAPLUS

CN Benzenemethanamine, N-(1-methylethyl)-3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]- (9CI) (CA INDEX NAME)




RN 428816-14-2 CAPLUS

CN Benzenemethanamine, N-(3-methoxyphenyl)-3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]- (9CI) (CA INDEX NAME)




RN 428816-15-3 CAPLUS


CN    Ethanol, 2-[[[3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenyl]methyl]amino]- (9CI)    (CA INDEX NAME)



IT **428816-16-4P 428816-17-5P**, tert-Butyl  
 4-(3-[2-[3-(4-morpholinylmethyl)phenoxy]ethoxy]-2-pyrazinyl)-1-  
 piperazinecarboxylate  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. of piperazinylpyrazines as antagonists of serotonin 5-HT<sub>2</sub>  
 receptor)  
 RN 428816-16-4 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[3-[2-(3-formylphenoxy)ethoxy]pyrazinyl]-,  
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 428816-17-5 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[3-[2-[3-(4-morpholinylmethyl)phenoxy]ethox  
 y]pyrazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



09/988966



RE.CNT 7      THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/988966

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS  
AN 2000:900625 CAPLUS  
DN 134:56689  
TI Preparation of pyrazinyl phenoxyethyl ethers as 5-HT<sub>2C</sub> receptor modulators  
IN Nilsson, Bjorn; Tejbrant, Jan; Pelcman, Benjamin; Ringberg, Erik; Thor, Markus; Nilsson, Jonas; Jonsson, Mattias  
PA Pharmacia & Upjohn AB, Swed.  
SO PCT Int. Appl., 151 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 2

*equiv to  
Ans. 1*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000076984	A2	20001221	WO 2000-SE1017	20000519
	WO 2000076984	A3	20010208		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP	1178973	A2	20020213	EP 2000-931877	20000519
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	BR 2000010783	A	20020409	BR 2000-10783	20000519
	NO 2001005686	A	20020115	NO 2001-5686	20011121
PRAI	SE 1999-1884	A	19990521		
	US 1999-137527P	P	19990603		
	WO 2000-SE1017	W	20000519		
OS	MARPAT 134:56689				
GI					



AB The title compds. (I) [wherein Ar = (un)substituted (hetero)aryl; A = O, S, SO<sub>2</sub>, NH, alkyl- or acyl-substituted N, or (un)satd., (un)substituted (hetero)alkylene chain which may contain a bridge to form a ring; B = CR<sub>4</sub>R<sub>5</sub>, OCR<sub>4</sub>R<sub>5</sub>, NR<sub>6</sub>CR<sub>4</sub>R<sub>5</sub>, NR<sub>6</sub>O, S, or SO<sub>2</sub>; R = (un)substituted cycloalkyl or (hetero)aryl; R<sub>1</sub> = (un)satd. (amino)azacyclic or satd. (amino)diazacyclic, (amino)azabicyclic, or diazabicyclic ring, or (CR<sub>4</sub>R<sub>5</sub>)<sub>x</sub>NR<sub>2a</sub>R<sub>3a</sub>; n = 0-1; R<sub>2a</sub> and R<sub>3a</sub> = independently H, Me, or Et, or



taken together with the N to which they are bound form a pyrrolidine, piperazine, or morpholine ring; R4, R5, and R6 = independently H or alkyl; x = 2-4] and their pharmaceutically acceptable salts were prepd. and tested as 5-HT2C receptor modulators. Examples include 235 syntheses, a tablet formulation, and pharmacol. tests. For instance, 2,3-dichloropyrazine and 2-phenoxyethanol were treated with t-BuONa in dioxane to give 2-chloro-3-(2-phenoxyethoxy)pyrazine (62%). The halopyrazine, piperazine, and K2CO3 in MeCN were stirred and heated to afford the desired 2-(phenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether (II) in 65% yield, which was then converted to the maleate salt. In an affinity assay using membranes prepd. from a transfected HEK293 cell line stably expressing the 5-HT2C receptor protein, I typically exhibited 5HT2C receptor affinity values (K1) ranging from 1 nM to 1500 nM. Specific values ranging from 5 nM to 377 nM were reported for 12 compds. Agonist efficacy at the 5-HT2C receptor for I were detd. by the ability of the compds. to mobilize intracellular Ca in transfected HEK293 cells, and typical max. responses of the agonists were in the range of 20-100% relative to the max. response of 5-HT (serotonin) at a concn. of 1 .mu.M. Acute toxicity studies in mice following oral administration of I showed that mortality typically occurred at doses between 200 mg/kg to 450 mg/kg body wt. I are useful for the treatment of serotonin-related disorders, such as eating disorders, esp. obesity, memory disorders, schizophrenia, mood disorders, anxiety disorders, pain, sexual dysfunctions, and urinary disorders (no data).

IT **313653-94-0P**, 2-(Phenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether

**313655-66-2P**, N-Phenyl-3-[2-[[3-(1-piperazinyl)-2-pyrazinyl]oxy]ethoxy]aniline **313655-69-5P**, [3-[2-[[3-(1-piperazinyl)-2-pyrazinyl]oxy]ethoxy]phenyl]methanol Maleate

**313655-74-2P**, 2-[2-[3-(Methoxymethyl)phenoxy]ethoxy]-3-(1-piperazinyl)pyrazine **313655-77-5P**, 3-[2-[[3-(1-piperazinyl)-2-pyrazinyl]oxy]ethoxy]benzamide **313655-79-7P**,

N-Phenyl-4-(2-[[3-(1-piperazinyl)-2-pyrazinyl]oxy]ethoxy)aniline

**313655-82-2P**, 2-(1-piperazinyl)-3-[2-[3-(trifluoromethoxy)phenoxy]ethoxy]pyrazine **313655-90-2P**,

2-[2-(3-Butoxyphenoxy)ethoxy]-3-(1-piperazinyl)pyrazine

**313655-93-5P**, 2-[2-(3-Trifluoromethylphenoxy)ethoxy]-3-(1-piperazinyl)pyrazine **313655-94-6P**, 2-[2-([1,1'-Biphenyl]-3-yloxy)ethoxyl-3-(1-piperazinyl)pyrazine **313655-99-1P**,

2-[4-[2-[[3-(1-piperazinyl)-2-pyrazinyl]oxy]ethoxy]phenoxy]ethanol

**313656-01-8P**, 2-[3-(2-[[3-(1-piperazinyl)-2-pyrazinyl]oxy]ethoxy)phenoxy]ethanol **313657-07-7P**,

2-(2-Phenoxy)ethyl 3-(2-methyl-1-piperazinyl)-2-pyrazinyl ether

**313658-60-5P**, 2-[2-[3-(2-Methoxyethoxy)phenoxy]ethoxy]-3-(1-piperazinyl)pyrazine


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of heterocyclylpyrazinyl phenoxyethoxy ether 5-HT2C receptor modulators by coupling of phenoxyethanols with 2,3-dichloropyrazine followed by addn. of heterocycles)


RN 313653-94-0 CAPLUS

CN Pyrazine, 2-(2-phenoxyethoxy)-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)

09/988966




RN 313655-66-2 CAPLUS  
CN Benzenamine, N-phenyl-3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]- (9CI)  
(CA INDEX NAME)



RN 313655-69-5 CAPLUS  
CN Benzenemethanol, 3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]-,  
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-68-4  
CMF C17 H22 N4 O3




CM 2

CRN 110-16-7  
CMF C4 H4 O4


Double bond geometry as shown.

09/988966




RN 313655-74-2 CAPLUS

CN Pyrazine, 2-[2-[3-(methoxymethyl)phenoxy]ethoxy]-3-(1-piperazinyl)- (9CI)  
(CA INDEX NAME)




RN 313655-77-5 CAPLUS

CN Benzamide, 3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]- (9CI) (CA INDEX NAME)



RN 313655-79-7 CAPLUS

CN Benzenamine, N-phenyl-4-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]- (9CI)  
(CA INDEX NAME)




RN 313655-82-2 CAPLUS

CN Pyrazine, 2-(1-piperazinyl)-3-[2-[3-(trifluoromethoxy)phenoxy]ethoxy]-


09/988966

(9CI) (CA INDEX NAME)




RN 313655-90-2 CAPLUS

CN Pyrazine, 2-[2-(3-butoxyphenoxy)ethoxy]-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 313655-93-5 CAPLUS


CN Pyrazine, 2-(1-piperazinyl)-3-[2-[3-(trifluoromethyl)phenoxy]ethoxy]- (9CI) (CA INDEX NAME)



RN 313655-94-6 CAPLUS


CN Pyrazine, 2-[2-([1,1'-biphenyl]-3-yloxy)ethoxy]-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)

09/988966




RN 313655-99-1 CAPLUS

CN Ethanol, 2-[4-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenoxy]- (9CI)  
(CA INDEX NAME)




RN 313656-01-8 CAPLUS

CN Ethanol, 2-[3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenoxy]- (9CI)  
(CA INDEX NAME)



RN 313657-07-7 CAPLUS


CN Pyrazine, 2-(2-methyl-1-piperazinyl)-3-(2-phenoxyethoxy)- (9CI) (CA INDEX NAME)



09/988966

RN 313658-60-5 CAPLUS

CN Pyrazine, 2-[2-[3-(2-methoxyethoxy)phenoxy]ethoxy]-3-(1-piperazinyl)-(9CI) (CA INDEX NAME)



IT **313654-07-8P**, 2-(4-Bromophenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether **313654-09-0P**, 2-(2-Chlorophenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether Trifluoroacetate **313654-11-4P**, 2-(4-Chlorophenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether Trifluoroacetate **313654-13-6P**, 2-Phenoxypropyl 3-(1-piperazinyl)-2-pyrazinyl ether Trifluoroacetate **313654-15-8P**, 2-Phenoxy-1-methylethyl 3-(1-piperazinyl)-2-pyrazinyl ether Trifluoroacetate **313654-17-0P**, 2-(2-Methoxyphenoxy)-1-methylethyl 3-(1-piperazinyl)-2-pyrazinyl ether Trifluoroacetate **313654-19-2P**, 2-(3-Methoxyphenoxy)-1-methylethyl 3-(1-piperazinyl)-2-pyrazinyl ether Trifluoroacetate **313654-21-6P**, 2-(2-Methylphenoxy)-1-methylethyl 3-(1-piperazinyl)-2-pyrazinyl ether Trifluoroacetate **313654-23-8P**, 2-(4-Methylphenoxy)-1-methylethyl 3-(1-piperazinyl)-2-pyrazinyl ether Trifluoroacetate **313654-51-2P**, 2-(Phenoxy)ethyl 3-(3-methyl-1-piperazinyl)-2-pyrazinyl ether **313654-52-3P**, 2-(4-Chlorophenoxy)ethyl 3-(3-methyl-1-piperazinyl)-2-pyrazinyl ether **313654-53-4P**, 2-(2-Methoxyphenoxy)-1-methylethyl 3-(3-methyl-1-piperazinyl)-2-pyrazinyl ether **313654-56-7P**, 2-(Phenoxy)ethyl 3-(4-ethyl-1-piperazinyl)-2-pyrazinyl ether **313654-57-8P**, 2-(2-Chlorophenoxy)ethyl 3-(4-ethyl-1-piperazinyl)-2-pyrazinyl ether **313654-58-9P**, 2-(4-Chlorophenoxy)ethyl 3-(4-ethyl-1-piperazinyl)-2-pyrazinyl ether **313654-60-3P**, 2-(2-Methoxyphenoxy)-1-methylethyl 3-(4-ethyl-1-piperazinyl)-2-pyrazinyl ether **313654-61-4P**, 2-(3-Bromophenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether **313654-82-9P**, 2-(2-Methoxyphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether **313654-86-3P**, 2-(4-n-Butoxyphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether Trifluoroacetate **313654-87-4P**, 2-(2-Isopropoxyphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether **313654-89-6P**, 2-(2,5-Difluorophenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether **313654-90-9P**, 2-(2,5-Difluorophenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether Trifluoroacetate **313654-91-0P**, 2-(3,5-Dimethoxyphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether **313654-92-1P** **313654-94-3P**, 2-(2,6-Dimethoxyphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether Trifluoroacetate **313654-95-4P**, 2-(2,3-Dimethoxyphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether **313654-97-6P**, 2-(2-Acetylphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether Trifluoroacetate **313654-99-8P**, 2-(2-Acetyl-5-methoxyphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether Trifluoroacetate **313655-01-5P**, 2-(2-Acetyl-3,5-dimethoxyphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether

Trifluoroacetate **313655-04-8P**, 2-(2-Fluoro-6-methoxyphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether  
**313655-05-9P**, 2-(2-Methoxy-4-methylphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether **313655-08-2P**,  
 2-(2-Chloro-4-methoxyphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether **313655-09-3P**, 2-[2-[2-Fluoro-5-(trifluoromethyl)phenoxy]ethoxy]-3-(1-piperazinyl)pyrazine **313655-12-8P**, 2-[2-[3-(Methylsulfonyl)phenoxy]ethoxy]-3-(1-piperazinyl)pyrazine  
**313655-14-0P**, 2-(2,3,6-Trifluorophenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether **313655-15-1P**, 2-(2,4,5-Trifluorophenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether **313655-16-2P**,  
 2-(2-Hydroxyphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether **313655-17-3P**, 2-(3-Hydroxyphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether **313655-18-4P**, 2-[3-(4-Morpholinyl)phenoxy]ethyl 3-(1-piperazinyl)-2-pyrazinyl ether **313655-21-9P**,  
 2-(2-Allylphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether **313655-22-0P**, 2-(3-Aminophenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether **313655-24-2P**, 2-(2,6-Difluorophenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether **313655-33-3P**,  
 3-(Phenoxy)propyl 3-(1-piperazinyl)-2-pyrazinyl ether Dihydrochloride **313655-34-4P**, 2-(2-Trifluoromethylphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether **313655-37-7P**,  
 2-(2-Methylthiophenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether Maleate **313655-39-9P**, 2-(2-Methylphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether Maleate **313655-40-2P**, 2-(2,5-Dimethylphenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether  
**313655-41-3P**, 2-(2-Fluorophenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether **313655-42-4P**, 2-(2-Fluorophenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether Maleate **313655-44-6P**,  
 2-(2-Cyanophenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether Maleate **313655-46-8P**, 2-[(1,1'-Biphenyl)-2-yloxy]ethyl 3-(1-piperazinyl)-2-pyrazinyl ether **313655-47-9P**, 4-(Phenoxy)butyl 3-(1-piperazinyl)-2-pyrazinyl ether Dihydrochloride **313655-49-1P**,  
 2-[2-(2-Fluoro-5-methylphenoxy)ethoxy]-3-(1-piperazinyl)pyrazine Fumarate **313655-52-6P**, 2-[2-(5-Fluoro-2-methoxyphenoxy)ethoxy]-3-(1-piperazinyl)pyrazine Fumarate **313655-54-8P**,  
 2-[2-(3-Fluorophenoxy)ethoxy]-3-(1-piperazinyl)pyrazine Maleate **313655-57-1P**, 2-[2-(3-Acetylphenoxy)ethoxy]-3-(1-piperazinyl)pyrazine **313655-58-2P**, 2-[2-(3-Acetylphenoxy)ethoxy]-3-(1-piperazinyl)pyrazine Maleate **313655-59-3P**,  
 2-[2-(3-Cyanophenoxy)ethoxy]-3-(1-piperazinyl)pyrazine **313655-61-7P**, 2-[2-(2,3-Difluorophenoxy)ethoxy]-3-(1-piperazinyl)pyrazine Fumarate **313655-64-0P**, 2-[2-(2,3,5-Trifluorophenoxy)ethoxy]-3-(1-piperazinyl)pyrazine Fumarate  
**313655-67-3P**, N-Phenyl-3-[2-[3-(1-piperazinyl)-2-pyrazinyl]oxy]ethoxy]aniline Fumarate **313655-75-3P**, 2-[2-[3-(Methoxymethyl)phenoxy]ethoxy]-3-(1-piperazinyl)pyrazine Maleate  
**313655-78-6P**, 3-[2-[3-(1-Piperazinyl)-2-pyrazinyl]oxy]ethoxy]benzamide Maleate **313655-80-0P**, N-Phenyl-4-[2-[3-(1-piperazinyl)-2-pyrazinyl]oxy]ethoxy]aniline Maleate  
**313655-81-1P**, N-[4-[2-[3-(1-Piperazinyl)-2-pyrazinyl]oxy]ethoxy]phenyl]acetamide **313655-83-3P**, 2-(1-Piperazinyl)-3-[2-[3-(trifluoromethoxy)phenoxy]ethoxy]pyrazine Maleate **313655-91-3P**, 2-[2-(3-Butoxyphenoxy)ethoxy]-3-(1-piperazinyl)pyrazine Maleate **313655-95-7P**, 2-[2-[(1,1'-Biphenyl)-3-yloxy]ethoxy]-3-(1-piperazinyl)pyrazine Maleate **313655-97-9P**,  
 2-[2-(3-Acetamidophenoxy)ethoxy]-3-(1-piperazinyl)pyrazine Maleate **313656-00-7P**, 2-[4-[2-[3-(1-Piperazinyl)-2-

pyrazinyl]oxy]ethoxy]phenoxy]ethanol Maleate **313656-02-9P**,  
 2-[3-(2-[[3-(1-Piperazinyl)-2-pyrazinyl]oxy]ethoxy]phenoxy]ethanol Maleate  
**313656-50-7P**, 2-[2-(2-Methoxy-5-methylphenoxy)ethoxy]-3-(1-  
 piperazinyl)pyrazine Maleate **313657-06-6P 313657-08-8P**  
 , 2-(2-Phenoxy)ethyl 3-(2-methyl-1-piperazinyl)-2-pyrazinyl ether Maleate  
**313657-11-3P**, (2R)-Methyl-1-[3-(2-phenoxyethoxy)-2-  
 pyrazinyl]piperazine Hydrochloride **313657-17-9P**,  
 (2S)-Methyl-1-[3-(2-phenoxyethoxy)-2-pyrazinyl]piperazine Hydrochloride  
**313657-46-4P**, 5,6-Dimethyl-2-(2-phenoxyethoxy)-3-(1-  
 piperazinyl)pyrazine Dihydrochloride **313658-09-2P**,  
 4-Methoxy-N,N-dimethyl-3-[2-[[3-(2R)-2-methylpiperazinyl]-2-  
 pyrazinyl]oxy]ethoxy]aniline Fumarate **313658-12-7P**,  
 (2R)-Methyl-1-[3-(2,5-dimethoxyphenoxyethoxy)-2-pyrazinyl]piperazine  
 Maleate **313658-45-6P**, 2-[2-[3-(2-Fluoroethoxy)phenoxy]ethoxy]-3-  
 (1-piperazinyl)pyrazine Trifluoroacetate **313658-47-8P**,  
 2-[2-[3-[2-(4-Methyl-1,3-thiazol-5-yl)ethoxy]phenoxy]ethoxy]-3-(1-  
 piperazinyl)pyrazine **313658-48-9P 313658-50-3P**,  
 2-[2-[3-(Cyclopropylmethoxy)phenoxy]ethoxy]-3-(1-piperazinyl)pyrazine  
 Trifluoroacetate **313658-52-5P**, 2-[2-[3-(3-  
 Butenyloxy)phenoxy]ethoxy]-3-(1-piperazinyl)pyrazine Trifluoroacetate  
**313658-54-7P**, N,N-Dimethyl-N-[2-[3-[2-[[3-(1-piperazinyl)-2-  
 pyrazinyl]oxy]ethoxy]phenoxy]ethyl]amine **313658-55-8P**,  
 N,N-Dimethyl-N-[2-[3-(2-[[3-(1-piperazinyl)-2-  
 pyrazinyl]oxy]ethoxy]phenoxy]ethyl]amine Trifluoroacetate  
**313658-57-0P**, 2-(1-Piperazinyl)-3-[2-[3-(tetrahydro-2H-pyran-4-  
 yloxy)phenoxy]ethoxy]pyrazine **313658-58-1P**, 2-(1-Piperazinyl)-3-  
 [2-[3-(tetrahydro-2H-pyran-4-yloxy)phenoxy]ethoxy]pyrazine  
 Trifluoroacetate **313658-63-8P**, 1-[2-[3-[2-[[3-(1-Piperazinyl)-2-  
 pyrazinyl]oxy]ethoxy]phenoxy]ethyl]-2-pyrrolidinone **313658-65-0P**  
 , 2-(1-Piperazinyl)-3-[2-[3-(tetrahydro-3-furanyloxy)phenoxy]ethoxy]pyrazi  
 ne **313658-67-2P**, 2-(1-Piperazinyl)-3-[2-[3-(tetrahydro-3-  
 furanylmethoxy)phenoxy]ethoxy]pyrazine **313658-70-7P**,  
 2-[[3-[2-[[3-(1-Piperazinyl)-2-pyrazinyl]oxy]ethoxy]phenoxy]methyl]benzoni  
 trile **313658-71-8P**, 2-[[3-[2-[[3-(1-Piperazinyl)-2-  
 pyrazinyl]oxy]ethoxy]phenoxy]methyl]benzonitrile Trifluoroacetate  
**313658-75-2P**, 2-[2-[3-(Benzyloxy)phenoxy]ethoxy]-3-(1-  
 piperazinyl)pyrazine Trifluoroacetate **313658-78-5P**,  
 2-(1-Piperazinyl)-3-[2-[3-[2-(2-pyridinyl)ethoxy]phenoxy]ethoxy]pyrazine  
**313658-79-6P**, 2-(1-Piperazinyl)-3-(2-[3-[2-(2-  
 pyridinyl)ethoxy]phenoxy]ethoxy]pyrazine Trifluoroacetate  
**313658-97-8P**, 2-(3-Methoxyphenoxy)ethyl 3-(1-piperazinyl)-2-  
 pyrazinyl ether **313659-07-3P**, (R)-2-Methyl-1-[3-(2-  
 phenoxyethoxy)-2-pyrazinyl]piperazine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heterocyclpyrazinyl phenoxyethoxy ether 5-HT<sub>2C</sub> receptor  
 modulators by coupling of phenoxyethanols with 2,3-dichloropyrazine  
 followed by addn. of heterocycles)

RN 313654-07-8 CAPLUS

CN Pyrazine, 2-[2-(2-bromophenoxy)ethoxy]-3-(1-piperazinyl)-, ethanedioate  
 (9CI) (CA INDEX NAME)


CM 1

CRN 313654-06-7

CMF C16 H19 Br N4 O2




09/988966



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 313654-09-0 CAPLUS

CN Pyrazine, 2-[2-(2-chlorophenoxy)ethoxy]-3-(1-piperazinyl)-, ethanedioate  
(9CI) (CA INDEX NAME)

CM 1

CRN 313654-08-9


CMF C16 H19 Cl N4 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




09/988966

RN 313654-11-4 CAPLUS  
CN Pyrazine, 2-[2-(4-chlorophenoxy)ethoxy]-3-(1-piperazinyl)-, ethanedioate (9CI) (CA INDEX NAME)


CM 1

CRN 313654-10-3  
CMF C16 H19 Cl N4 O2



CM 2


CRN 144-62-7  
CMF C2 H2 O4



RN 313654-13-6 CAPLUS  
CN Pyrazine, 2-(2-phenoxypropoxy)-3-(1-piperazinyl)-, ethanedioate (9CI) (CA INDEX NAME)

CM 1


CRN 313654-12-5  
CMF C17 H22 N4 O2



CM 2

CRN 144-62-7  
CMF C2 H2 O4

09/988966




RN 313654-15-8 CAPLUS

CN Pyrazine, 2-(1-methyl-2-phenoxyethoxy)-3-(1-piperazinyl)-, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 313654-14-7


CMF C17 H22 N4 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 313654-17-0 CAPLUS


CN Pyrazine, 2-[2-(2-methoxyphenoxy)-1-methylethoxy]-3-(1-piperazinyl)-, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 313654-16-9

CMF C18 H24 N4 O3


09/988966



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 313654-19-2 CAPLUS

CN Pyrazine, 2-[2-(3-methoxyphenoxy)-1-methylethoxy]-3-(1-piperazinyl)-, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 313654-18-1


CMF C18 H24 N4 O3



CM 2

CRN 144-62-7

CMF C2 H2 O4



09/988966


RN 313654-21-6 CAPLUS

CN Pyrazine, 2-[1-methyl-2-(2-methylphenoxy)ethoxy]-3-(1-piperazinyl)-, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 313654-20-5


CMF C18 H24 N4 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 313654-23-8 CAPLUS

CN Pyrazine, 2-[1-methyl-2-(4-methylphenoxy)ethoxy]-3-(1-piperazinyl)-, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 313654-22-7


CMF C18 H24 N4 O2




CM 2

09/988966


CRN 144-62-7  
CMF C2 H2 O4




RN 313654-51-2 CAPLUS  
CN Pyrazine, 2-(3-methyl-1-piperazinyl)-3-(2-phenoxyethoxy)- (9CI) (CA INDEX NAME)



RN 313654-52-3 CAPLUS  
CN Pyrazine, 2-[2-(4-chlorophenoxy)ethoxy]-3-(3-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 313654-53-4 CAPLUS  
CN Pyrazine, 2-[2-(2-methoxyphenoxy)-1-methylethoxy]-3-(3-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 313654-56-7 CAPLUS


09/988966

CN Pyrazine, 2-(4-ethyl-1-piperazinyl)-3-(2-phenoxyethoxy)- (9CI) (CA INDEX NAME)




RN 313654-57-8 CAPLUS

CN Pyrazine, 2-[2-(2-chlorophenoxy)ethoxy]-3-(4-ethyl-1-piperazinyl)- (9CI)  
(CA INDEX NAME)



RN 313654-58-9 CAPLUS


CN Pyrazine, 2-[2-(4-chlorophenoxy)ethoxy]-3-(4-ethyl-1-piperazinyl)- (9CI)  
(CA INDEX NAME)



RN 313654-60-3 CAPLUS


CN Pyrazine, 2-(4-ethyl-1-piperazinyl)-3-[2-(2-methoxyphenoxy)-1-methylethoxy]- (9CI) (CA INDEX NAME)

09/988966




RN 313654-61-4 CAPLUS

CN Pyrazine, 2-[2-(3-bromophenoxy)ethoxy]-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 313654-82-9 CAPLUS

CN Pyrazine, 2-[2-(2-methoxyphenoxy)ethoxy]-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 313654-86-3 CAPLUS

CN Pyrazine, 2-[2-(4-butoxyphenoxy)ethoxy]-3-(1-piperazinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 313654-85-2

CMF C20 H28 N4 O3




09/988966



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 313654-87-4 CAPLUS


CN Pyrazine, 2-[2-[2-(1-methylethoxy)phenoxy]ethoxy]-3-(1-piperazinyl)- (9CI)  
(CA INDEX NAME)



RN 313654-89-6 CAPLUS

CN Pyrazine, 2-[2-(2,5-difluorophenoxy)ethoxy]-3-(1-piperazinyl)- (9CI) (CA  
INDEX NAME)


09/988966



RN 313654-90-9 CAPLUS  
CN Pyrazine, 2-[2-(2,5-difluorophenoxy)ethoxy]-3-(1-piperazinyl)-,  
trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 313654-89-6  
CMF C16 H18 F2 N4 O2




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 313654-91-0 CAPLUS  
CN Pyrazine, 2-[2-(3,5-dimethoxyphenoxy)ethoxy]-3-(1-piperazinyl)- (9CI) (CA  
INDEX NAME)

09/988966



RN 313654-92-1 CAPLUS

CN Pyrazine, 2-[2-(2-methoxy-5-nitrophenoxy)ethoxy]-3-(1-piperazinyl)-,  
hydrochloride (2:1) (9CI) (CA INDEX NAME)



● 1/2 HCl


RN 313654-94-3 CAPLUS

CN Pyrazine, 2-[2-(2,6-dimethoxyphenoxy)ethoxy]-3-(1-piperazinyl)-,  
trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 313654-93-2

CMF C18 H24 N4 O4




09/988966

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 313654-95-4 CAPLUS

CN Pyrazine, 2-[2-(2,3-dimethoxyphenoxy)ethoxy]-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 313654-97-6 CAPLUS

CN Ethanone, 1-[2-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 313654-96-5

CMF C18 H22 N4 O3




CM 2

CRN 76-05-1

CMF C2 H F3 O2


09/988966



RN 313654-99-8 CAPLUS  
CN Ethanone, 1-[4-methoxy-2-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 313654-98-7  
CMF C19 H24 N4 O4



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 313655-01-5 CAPLUS  
CN Ethanone, 1-[2,4-dimethoxy-6-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 313655-00-4  
CMF C20 H26 N4 O5


09/988966



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 313655-04-8 CAPLUS


CN Pyrazine, 2-[2-(2-fluoro-6-methoxyphenoxy)ethoxy]-3-(1-piperazinyl)- (9CI)  
(CA INDEX NAME)



RN 313655-05-9 CAPLUS


CN Pyrazine, 2-[2-(2-methoxy-4-methylphenoxy)ethoxy]-3-(1-piperazinyl)- (9CI)  
(CA INDEX NAME)

09/988966




RN 313655-08-2 CAPLUS

CN Pyrazine, 2-[2-(2-chloro-4-methoxyphenoxy)ethoxy]-3-(1-piperazinyl)- (9CI)  
(CA INDEX NAME)



RN 313655-09-3 CAPLUS


CN Pyrazine, 2-[2-[2-fluoro-4-(trifluoromethyl)phenoxy]ethoxy]-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 313655-12-8 CAPLUS


CN Pyrazine, 2-[2-[3-(methylsulfonyl)phenoxy]ethoxy]-3-(1-piperazinyl)- (9CI)  
(CA INDEX NAME)

09/988966




RN 313655-14-0 CAPLUS

CN Pyrazine, 2-(1-piperazinyl)-3-[2-(2,3,6-trifluorophenoxy)ethoxy]- (9CI)  
(CA INDEX NAME)



RN 313655-15-1 CAPLUS

CN Pyrazine, 2-(1-piperazinyl)-3-[2-(2,4,5-trifluorophenoxy)ethoxy]- (9CI)  
(CA INDEX NAME)




RN 313655-16-2 CAPLUS

CN Phenol, 2-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]- (9CI) (CA INDEX  
NAME)




09/988966




RN 313655-17-3 CAPLUS

CN Phenol, 3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]- (9CI) (CA INDEX NAME)



RN 313655-18-4 CAPLUS


CN Morpholine, 4-[3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 313655-21-9 CAPLUS


CN Pyrazine, 2-(1-piperazinyl)-3-[2-[2-(2-propenyl)phenoxy]ethoxy]- (9CI) (CA INDEX NAME)

09/988966




RN 313655-22-0 CAPLUS

CN Benzenamine, 3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]- (9CI) (CA INDEX NAME)



RN 313655-24-2 CAPLUS


CN Pyrazine, 2-[2-(2,6-difluorophenoxy)ethoxy]-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 313655-33-3 CAPLUS

CN Pyrazine, 2-(3-phenoxypropoxy)-3-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)


09/988966



● 2 HCl

RN 313655-34-4 CAPLUS

CN Pyrazine, 2-(1-piperazinyl)-3-[2-[2-(trifluoromethyl)phenoxy]ethoxy]-  
(9CI) (CA INDEX NAME)




RN 313655-37-7 CAPLUS

CN Pyrazine, 2-[2-[2-(methylthio)phenoxy]ethoxy]-3-(1-piperazinyl)-,  
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-36-6

CMF C17 H22 N4 O2 S




CM 2

CRN 110-16-7

CMF C4 H4 O4

09/988966

Double bond geometry as shown.




RN 313655-39-9 CAPLUS

CN Pyrazine, 2-[2-(2-methylphenoxy)ethoxy]-3-(1-piperazinyl)-,  
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-38-8

CMF C17 H22 N4 O2




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 313655-40-2 CAPLUS


CN Pyrazine, 2-[2-(2,5-dimethylphenoxy)ethoxy]-3-(1-piperazinyl)- (9CI) (CA  
INDEX NAME)

09/988966



RN 313655-41-3 CAPLUS

CN Pyrazine, 2-[2-(2-fluorophenoxy)ethoxy]-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 313655-42-4 CAPLUS

CN Pyrazine, 2-[2-(2-fluorophenoxy)ethoxy]-3-(1-piperazinyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-41-3

CMF C16 H19 F N4 O2




CM 2

CRN 110-16-7

CMF C4 H4 O4

09/988966


Double bond geometry as shown.



RN 313655-44-6 CAPLUS  
CN Benzonitrile, 2-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]-,  
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 313655-43-5  
CMF C17 H19 N5 O2



CM 2


CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.




RN 313655-46-8 CAPLUS  
CN Pyrazine, 2-[2-([1,1'-biphenyl]-2-yloxy)ethoxy]-3-(1-piperazinyl)- (9CI)  
(CA INDEX NAME)

09/988966



RN 313655-47-9 CAPLUS

CN Pyrazine, 2-(4-phenoxybutoxy)-3-(1-piperazinyl)-, dihydrochloride (9CI)  
(CA INDEX NAME)



● 2 HCl


RN 313655-49-1 CAPLUS

CN Pyrazine, 2-[2-(2-fluoro-5-methylphenoxy)ethoxy]-3-(1-piperazinyl)-,  
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-48-0

CMF C17 H21 F N4 O2




CM 2

CRN 110-17-8

CMF C4 H4 O4

09/988966


Double bond geometry as shown.



RN 313655-52-6 CAPLUS  
CN Pyrazine, 2-[2-(5-fluoro-2-methoxyphenoxy)ethoxy]-3-(1-piperazinyl)-,  
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 313655-51-5  
CMF C17 H21 F N4 O3



CM 2

CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.




RN 313655-54-8 CAPLUS  
CN Pyrazine, 2-[2-(3-fluorophenoxy)ethoxy]-3-(1-piperazinyl)-,  
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-53-7  
CMF C16 H19 F N4 O2



09/988966




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 313655-57-1 CAPLUS

CN Ethanone, 1-[3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenyl]- (9CI)  
(CA INDEX NAME)



RN 313655-58-2 CAPLUS


CN Ethanone, 1-[3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-57-1

CMF C18 H22 N4 O3

09/988966




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 313655-59-3 CAPLUS

CN Benzonitrile, 3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]- (9CI) (CA INDEX NAME)



RN 313655-61-7 CAPLUS


CN Pyrazine, 2-[2-(2,3-difluorophenoxy)ethoxy]-3-(1-piperazinyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-60-6

CMF C16 H18 F2 N4 O2

09/988966




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 313655-64-0 CAPLUS

CN Pyrazine, 2-(1-piperazinyl)-3-[2-(2,3,5-trifluorophenoxy)ethoxy]-,  
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-63-9

CMF C16 H17 F3 N4 O2




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



09/988966


RN 313655-67-3 CAPLUS

CN Benzenamine, N-phenyl-3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]-,  
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-66-2

CMF C22 H25 N5 O2




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 313655-75-3 CAPLUS

CN    Pyrazine, 2-[2-[3-(methoxymethyl)phenoxy]ethoxy]-3-(1-piperazinyl)-,  
 (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-74-2


CMFC18H24N4O3

CM 2

09/988966

CRN 110-16-7  
CMF C4 H4 O4


Double bond geometry as shown.



RN 313655-78-6 CAPLUS  
CN Benzanide, 3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]-,  
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 313655-77-5  
CMF C17 H21 N5 O3



CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.




RN 313655-80-0 CAPLUS  
CN Benzenamine, N-phenyl-4-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]-,  
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-79-7  
CMF C22 H25 N5 O2

09/988966




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 313655-81-1 CAPLUS

CN Acetamide, N-[4-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenyl]- (9CI)  
(CA INDEX NAME)



RN 313655-83-3 CAPLUS


CN Pyrazine, 2-(1-piperazinyl)-3-[2-[3-(trifluoromethoxy)phenoxy]ethoxy]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-82-2

CMF C17 H19 F3 N4 O3

09/988966




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 313655-91-3 CAPLUS

CN Pyrazine, 2-[2-(3-butoxyphenoxy)ethoxy]-3-(1-piperazinyl)-,  
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-90-2

CMF C20 H28 N4 O3




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.


09/988966



RN 313655-95-7 CAPLUS  
CN Pyrazine, 2-[2-([1,1'-biphenyl]-3-yloxy)ethoxy]-3-(1-piperazinyl)-,  
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 313655-94-6  
CMF C22 H24 N4 O2



CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.




RN 313655-97-9 CAPLUS  
CN Acetamide, N-[3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenyl]-,  
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-96-8  
CMF C18 H23 N5 O3



09/988966




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 313656-00-7 CAPLUS

CN Ethanol, 2-[4-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenoxy]-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 313655-99-1

CMF C18 H24 N4 O4




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.

09/988966




RN 313656-02-9 CAPLUS

CN Ethanol, 2-[3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenoxy]-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 313656-01-8

CMF C18 H24 N4 O4




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 313656-50-7 CAPLUS


CN Pyrazine, 2-[2-(2-methoxy-5-methylphenoxy)ethoxy]-3-(1-piperazinyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313656-49-4

CMF C18 H24 N4 O3

09/988966




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 313657-06-6 CAPLUS

CN Pyrazine, 2-(4-methyl-1-piperazinyl)-3-(2-phenoxyethoxy)-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 313657-08-8 CAPLUS


CN Pyrazine, 2-(2-methyl-1-piperazinyl)-3-(2-phenoxyethoxy)-,  
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313657-07-7

CMF C17 H22 N4 O2

09/988966




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 313657-11-3 CAPLUS

CN Pyrazine, 2-[(2R)-2-methyl-1-piperazinyl]-3-(2-phenoxyethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 313657-17-9 CAPLUS

CN Pyrazine, 2-[(2S)-2-methyl-1-piperazinyl]-3-(2-phenoxyethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/988966



● HCl

RN 313657-46-4 CAPLUS

CN Pyrazine, 2,3-dimethyl-5-(2-phenoxyethoxy)-6-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 313658-09-2 CAPLUS


CN Benzenamine, 4-methoxy-N,N-dimethyl-3-[2-[[3-[(2R)-2-methyl-1-piperazinyl]pyrazinyl]oxy]ethoxy]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313658-08-1

CMF C20 H29 N5 O3

Absolute stereochemistry.




09/988966

CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 313658-12-7 CAPLUS


CN Pyrazine, 2-[2-(2,5-dimethoxyphenoxy)ethoxy]-3-[(2R)-2-methyl-1-piperazinyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313658-11-6

CMF C19 H26 N4 O4

Absolute stereochemistry.




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 313658-45-6 CAPLUS


CN Pyrazine, 2-[2-[3-(2-fluoroethoxy)phenoxy]ethoxy]-3-(1-piperazinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 313658-44-5

09/988966


CMF C18 H23 F N4 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 313658-47-8 CAPLUS

CN Pyrazine, 2-[2-[3-[2-(4-methyl-5-thiazolyl)ethoxy]phenoxy]ethoxy]-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 313658-48-9 CAPLUS


CN Pyrazine, 2-[2-[3-[2-(4-methyl-5-thiazolyl)ethoxy]phenoxy]ethoxy]-3-(1-piperazinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 313658-47-8

CMF C22 H27 N5 O3 S


09/988966



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313658-50-3 CAPLUS

CN Pyrazine, 2-[2-[3-(cyclopropylmethoxy)phenoxy]ethoxy]-3-(1-piperazinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 313658-49-0

CMF C20 H26 N4 O3




CM 2

CRN 76-05-1

CMF C2 H F3 O2



09/988966




RN 313658-52-5 CAPLUS

CN Pyrazine, 2-[2-[3-(3-butenyloxy)phenoxy]ethoxy]-3-(1-piperazinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 313658-51-4


CMF C20 H26 N4 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 313658-54-7 CAPLUS

CN Ethanamine, N,N-dimethyl-2-[3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)



09/988966


RN 313658-55-8 CAPLUS

CN Ethanamine, N,N-dimethyl-2-[3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenoxy]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 313658-54-7


CMF C20 H29 N5 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 313658-57-0 CAPLUS

CN Pyrazine, 2-(1-piperazinyl)-3-[2-[3-[(tetrahydro-2H-pyran-4-yl)oxy]phenoxy]ethoxy]- (9CI) (CA INDEX NAME)




RN 313658-58-1 CAPLUS

CN Pyrazine, 2-(1-piperazinyl)-3-[2-[3-[(tetrahydro-2H-pyran-4-yl)oxy]phenoxy]ethoxy]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


09/988966

CRN 313658-57-0  
CMF C21 H28 N4 O4




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 313658-63-8 CAPLUS  
CN 2-Pyrrolidinone, 1-[2-[3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 313658-65-0 CAPLUS  
CN Pyrazine, 2-(1-piperazinyl)-3-[2-[3-[(tetrahydro-2-furanyl)oxy]phenoxy]ethoxy]- (9CI) (CA INDEX NAME)

09/988966




RN 313658-67-2 CAPLUS

CN Pyrazine, 2-(1-piperazinyl)-3-[2-[3-[(tetrahydro-2-furanyl)methoxy]phenoxy]ethoxy]- (9CI) (CA INDEX NAME)



RN 313658-70-7 CAPLUS

CN Benzonitrile, 2-[[3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 313658-71-8 CAPLUS


CN Benzonitrile, 2-[[3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]phenoxy]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 313658-70-7

CMF C24 H25 N5 O3


09/988966



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313658-75-2 CAPLUS

CN Pyrazine, 2-[2-[3-(phenylmethoxy)phenoxy]ethoxy]-3-(1-piperazinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 313658-74-1

CMF C23 H26 N4 O3




CM 2

CRN 76-05-1


CMF C2 H F3 O2

09/988966



RN 313658-78-5 CAPLUS

CN Pyrazine, 2-(1-piperazinyl)-3-[2-[3-[2-(2-pyridinyl)ethoxy]phenoxy]ethoxy]-(9CI) (CA INDEX NAME)




RN 313658-79-6 CAPLUS

CN Pyrazine, 2-(1-piperazinyl)-3-[2-[3-[2-(2-pyridinyl)ethoxy]phenoxy]ethoxy]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 313658-78-5


CMF C23 H27 N5 O3



CM 2

CRN 76-05-1


CMF C2 H F3 O2



09/988966

RN 313658-97-8 CAPLUS


CN Pyrazine, 2-[2-(3-methoxyphenoxy)ethoxy]-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 313659-07-3 CAPLUS

CN Pyrazine, 2-[(2R)-2-methyl-1-piperazinyl]-3-(2-phenoxyethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **313655-71-9P**, 2-[2-[3-(Dimethoxymethyl)phenoxy]ethoxy]-3-(1-piperazinyl)pyrazine **313655-73-1P** **313657-10-2P**, 2-(2-Phenoxy)ethyl 3-(4-benzyl-2-methyl-1-piperazinyl)-2-pyrazinyl ether **313658-46-7P**, tert-Butyl 4-[3-[2-(3-hydroxyphenoxy)ethoxy]-2-pyrazinyl]-1-piperazinecarboxylate **313658-62-7P**, tert-Butyl 4-[3-[2-[3-(2-methoxyethoxy)phenoxy]ethoxy]-2-pyrazinyl]-1-piperazinecarboxylate  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of heterocyclpyrazinyl phenoxyethoxy ether 5-HT<sub>2C</sub> receptor modulators by coupling of phenoxyethanols with 2,3-dichloropyrazine followed by addn. of heterocycles)

RN 313655-71-9 CAPLUS

CN Pyrazine, 2-[2-[3-(dimethoxymethyl)phenoxy]ethoxy]-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)


09/988966



RN 313655-73-1 CAPLUS  
CN Benzaldehyde, 3-[2-[[3-(1-piperazinyl)pyrazinyl]oxy]ethoxy]-, acetate  
(10:17) (9CI) (CA INDEX NAME)


CM 1

CRN 313655-72-0  
CMF C17 H20 N4 O3




CM 2

CRN 64-19-7  
CMF C2 H4 O2



RN 313657-10-2 CAPLUS  
CN Pyrazine, 2-[2-methyl-4-(phenylmethyl)-1-piperazinyl]-3-(2-phenoxyethoxy)-  
(9CI) (CA INDEX NAME)






09/988966


RN 313658-46-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-[2-(3-hydroxyphenoxy)ethoxy]pyrazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 313658-62-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-[2-[3-(2-methoxyethoxy)phenoxy]ethoxy]pyrazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **313653-95-1P**, 2-(Phenoxy)ethyl 3-(1-piperazinyl)-2-pyrazinyl ether  
Maleate

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of heterocyclpyrazinyl phenoxyethoxy ether 5-HT2C receptor modulators by coupling phenoxyethanols with 2,3-dichloropyrazine followed by addn. of heterocycles)

RN 313653-95-1 CAPLUS


CN Pyrazine, 2-(2-phenoxyethoxy)-3-(1-piperazinyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 313653-94-0

CMF C16 H20 N4 O2

09/988966




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



09/988966

=> file caold

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	16.11	182.87
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.95	-1.95

FILE 'CAOLD' ENTERED AT 12:18:10 ON 02 JAN 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s 15

L7 0 L5

=> log h

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.40	183.27
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-1.95

SESSION WILL BE HELD FOR 60 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 12:18:18 ON 02 JAN 2003